Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

• Päätekijät: Silvia Pelligra (Tekijä), Natalia Buza (Tekijä), Pei Hui (Tekijä), Stefania Bellone (Tekijä), Burak Zeybek (Tekijä), Elena Ratner (Tekijä), Peter E. Schwartz (Tekijä), Giovanni Scambia (Tekijä), Alessandro D. Santin (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2020-05-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment...